Trial Profile

Tisagenlecleucel Versus Standard of Care in Adult Patients With Relapsed or Refractory Aggressive B-cell Non-Hodgkin Lymphoma: A Randomized, Open Label, Phase III Trial (BELINDA)

Status: Active, no longer recruiting

Phase of Trial: Phase III

Latest Information Update: 10 Jul 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Tisagenlecleucel (Primary) ; Bendamustine; Carboplatin; Carmustine; Cisplatin; Cyclophosphamide; Cytarabine; Dexamethasone; Etoposide; Fludarabine; Gemcitabine; Ibrutinib; Ifosfamide; Lenalidomide; Melphalan; Mesna; Oxaliplatin; Rituximab; Tocilizumab
Indications B-cell lymphoma; Diffuse large B cell lymphoma; Follicular lymphoma; Non-Hodgkin's lymphoma
Focus Registrational; Therapeutic Use
Acronyms BELINDA
Sponsors Novartis; Novartis Pharma A.G.; Novartis Pharmaceuticals

23 Apr 2025 Planned End Date changed from 14 Feb 2026 to 11 Feb 2026.
23 Jun 2023 This study has been completed in Belgium, according to European Clinical Trials Database.
31 Oct 2022 Planned End Date changed from 16 Aug 2028 to 14 Feb 2026.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com